Stockscreener 앱 받기
2.63
1.54%
0.04
시장 영업 전:
2.67
0.04
+1.52%
전일 마감가:
$2.59
열려 있는:
$2.62
하루 거래량:
2.53M
Relative Volume:
1.39
시가총액:
$288.71M
수익:
-
순이익/손실:
$-209.38M
주가수익비율:
-1.4013
EPS:
-1.8768
순현금흐름:
$-179.81M
1주 성능:
-12.91%
1개월 성능:
-29.30%
6개월 성능:
-26.54%
1년 성능:
-19.33%
1일 변동 폭
$2.5501
$2.73
1주일 범위
$2.51
$3.025
52주 변동 폭
$2.51
$5.45
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
명칭
Rocket Pharmaceuticals Inc
전화
646-440-9100
주소
350 FIFTH AVENUE, NEW YORK, NY
Compare RCKT vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RCKT
Rocket Pharmaceuticals Inc
|
2.63 | 284.87M | 0 | -209.38M | -179.81M | -1.8768 |
VRTX
Vertex Pharmaceuticals Inc
|
522.81 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
758.27 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
192.57 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
958.91 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.26 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-18 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2025-08-20 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-07-25 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-05-30 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-05-28 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-05-28 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-05-28 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-05-28 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-05-28 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-27 | 다운그레이드 | Needham | Buy → Hold |
| 2025-05-27 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-03-12 | 개시 | BMO Capital Markets | Outperform |
| 2024-12-30 | 개시 | Wedbush | Outperform |
| 2024-12-18 | 개시 | Jefferies | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-04-02 | 개시 | Goldman | Neutral |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-01 | 개시 | Morgan Stanley | Overweight |
| 2022-11-08 | 개시 | Canaccord Genuity | Buy |
| 2022-11-01 | 개시 | BTIG Research | Buy |
| 2022-07-08 | 개시 | Raymond James | Outperform |
| 2021-10-20 | 재개 | Cowen | Outperform |
| 2021-03-02 | 개시 | Stifel | Buy |
| 2021-02-18 | 개시 | Needham | Buy |
| 2020-12-16 | 개시 | UBS | Buy |
| 2020-12-08 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-07-02 | 개시 | JP Morgan | Overweight |
| 2020-06-25 | 재개 | BofA/Merrill | Buy |
| 2020-06-01 | 재개 | Oppenheimer | Outperform |
| 2019-11-06 | 개시 | Chardan Capital Markets | Buy |
| 2019-09-26 | 개시 | Piper Jaffray | Overweight |
| 2019-04-23 | 개시 | Robert W. Baird | Outperform |
| 2019-03-15 | 개시 | BofA/Merrill | Buy |
| 2019-02-05 | 개시 | Oppenheimer | Outperform |
| 2018-09-13 | 개시 | Ladenburg Thalmann | Buy |
| 2018-07-10 | 개시 | William Blair | Outperform |
모두보기
Rocket Pharmaceuticals Inc 주식(RCKT)의 최신 뉴스
RCKT Stock Dives Despite Gene Therapy Approval — Wall Street Dismisses Sell-Off - Stocktwits
Rocket Pharmaceuticals Advances Danon Disease Gene Therapy Trial With FDA Alignment - streetwisereports.com
Rocket Pharmaceuticals, Inc. (RCKT) Stock Price, News, Quote & History - Yahoo! Finance Canada
Rocket Pharmaceuticals (RCKT) Gets FDA Alignment on Heart Drug Trial. Can it Ease Safety Concerns? - Yahoo Finance
Rocket Pharmaceuticals stock holds focus on clinical milestones - AD HOC NEWS
Have Insiders Sold Rocket Pharmaceuticals Shares Recently? - simplywall.st
RCKT Aligns With FDA on Completing Phase II Study in Danon Disease - The Globe and Mail
Needham Upgrade Boosts Rocket Pharmaceuticals (RCKT) on FDA Tria - GuruFocus
Rocket Pharma stock upgraded at Needham (RCKT:NASDAQ) - Seeking Alpha
Leerink Partners Maintains Rocket Pharmaceuticals(RCKT.US) With Hold Rating - Moomoo
RCKT Reiterates by Wedbush -- Price Target Maintained at $15 - GuruFocus
Rocket Pharmaceuticals’ FDA Decision Clears ‘Meaningful Regulatory Overhang,’ Says Needham — Sees 150% Upside Potential In RCKT Stock - Yahoo Finance
Needham Upgrades Rocket Pharmaceuticals (RCKT) to Buy After FDA Trial Design Approval - GuruFocus
Rocket Pharmaceuticals general counsel sells $256,463 in RCKT shares By Investing.com - Investing.com South Africa
Rocket Pharmaceuticals (RCKT) counsel sells shares to cover RSU tax bill - stocktitan.net
Former Rocket Pharmaceuticals (RCKT) executive plans stock sale tied to equity award taxes - Stock Titan
Rocket Pharma Jumps as FDA Backs 12-Patient Pivotal Plan for Danon Gene Therapy - finance.biggo.com
Rocket Pharma gets FDA alignment on Danon disease trial By Investing.com - Investing.com Nigeria
RCKT Maintained by Chardan Capital -- Price Target Stays at $11. - GuruFocus
Rocket Pharmaceuticals Secures FDA Agreement on RP-A501 Phase 2 Trial for Danon Disease - Kalkine Media
Rocket Pharmaceuticals Shares Rise 8% After FDA Alignment on Danon Disease Trial - Yahoo Finance
Why is Rocket Pharmaceuticals stock down 5% today? By Investing.com - Investing.com Canada
Rocket Pharma Gets FDA Alignment On This Key Trial -- A Look At Some Key Highlights - Yahoo Finance
Form 8K Rocket Pharmaceuticals Inc For: 15 September By Investing.com - Investing.com Nigeria
Rocket Pharmaceuticals (RCKT) Advances Phase 2 Trial with FDA Ag - GuruFocus
Rocket Pharmaceuticals Says FDA Confirms Path to Complete Phase 2 Danon Disease Trial - marketscreener.com
Rocket Pharma gets FDA alignment on Danon disease trial - Investing.com
RCKT 8-K FilingsRocket Pharmaceuticals, Inc. SEC 8-K - Stock Titan
Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease - businesswire.com
Former Rocket Pharmaceuticals (RCKT) officer plans to sell 6,857 shares under an SEC trading rule - Stock Titan
Rocket Pharma (RCKT) executive plans sale of 75K shares tied to vested stock taxes - Stock Titan
Former Rocket Pharma (NASDAQ: RCKT) exec plans stock sale - Stock Titan
Rocket Pharmaceuticals Inc. (RCKT) Key Financial Ratios – Valuation, Profitability & More - Value Research
Rocket Pharmaceuticals at cantor healthcare conference: cardiomyopathy focus By Investing.com - Investing.com Canada
Rocket Pharmaceuticals at cantor healthcare conference: cardiomyopathy focus - Investing.com
Rocket Pharmaceuticals (RCKT) Up 6% Since Last Earnings Report: Can It Continue? - Yahoo Finance
RCKT News | ROCKET PHARMACEUTICALS INC (NASDAQ:RCKT) - ChartMill
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences - Yahoo Finance
Rocket Pharma (NASDAQ: RCKT) to pull 2026 warrant listing - Stock Titan
Chardan assumes Rocket Pharmaceuticals stock coverage with buy rating By Investing.com - Investing.com Nigeria
Chardan assumes Rocket Pharmaceuticals stock coverage with buy rating - Investing.com
Rocket Pharmaceuticals (RCKT) Jumps 6.6% to $3.86 as Buyers Defend Key Support LevelGap Up Stocks - vinanet.vn
Rocket Pharmaceuticals (RCKT) Surges 6.6% to $3.86 as Gene Therapy Stock Tests Key ResistanceJelly Roll Trade - careplusvn.com
New Jersey's Rocket Pharma Strikes New Pay Deal For Its GC - Law360
Rocket Pharmaceuticals, Inc. Sued for Securities Law Violations - GuruFocus
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Rocket Pharmaceuticals general counsel Martin Wilson sells $2,133 in stock By Investing.com - Investing.com South Africa
Rocket Pharmaceuticals Inc (RCKT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.29%
0.24%
자본화:
|
볼륨(24시간):